April 2022 Top Biopharma Deal: Harbour BioMed – AstraZeneca Bispecific Antibody for Cancer Treatment

by | May 10, 2022

April 2022 Top Biopharma Deal Upfront

Harbour BioMed development and commercialization deal with AstraZeneca for solid tumors

Announced: April 6, 2022

Total Deal Value: $350M

Upfront Cash: $25M

Upfront Equity: n/a

Option Payments: n/a

Milestones: up to $325M

Royalty: Undisclosed tiered royalties

Cost and Profit Split: n/a

The Asset:

Harbour BioMed’s HBM7022 CLDN18.2xCD3 bispecific antibody for solid tumors, including gastric and pancreatic cancers

Deal Structure:

Development and Commercial License

Partnership Features:

Collaborative Development, No Shared Cost

The Details:

  • Harbour BioMed granted AstraZeneca exclusive, worldwide rights to develop and commercialize its HBM7022 CLDN18.2xCD3 bispecific antibody developed using HBM’s HCAb based Immune Cell Engagers (HBICE) platform for the treatment of solid tumors, including gastric and pancreatic cancer.
  • AstraZeneca will be responsible for all costs for development and commercialization.
  • HBM will receive $25M up front and is eligible for up to $325M in development, regulatory, and commercial milestones, plus undisclosed tiered royalties.

Last Month:

Congrats to Harbour BioMed and AstraZeneca for landing DealForma’s April 2022 Top Biopharma Deal. Last month’s Deal of the Month was IGM Biosciences – Sanofi IgM antibody platform for Cancer and immunology/inflammation treatment. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

Want data for your analysis? Want us to do it? Subscribers get both.

Schedule your demo of the DealForma database to see how we help you get better reports done faster.


Deal Profiles


Funding Rounds


Company Profiles


Product Profiles


Clinical Trials


Business Developers

Specifically for Biotech, Pharma, Device, and Diagnostics

Get more done.

Stop cleaning data or getting lost in legacy databases. We built DealForma to help you be better and faster at business research. Schedule your customized demo to see how DealForma helps you impress your boss and sign-off early.

More Research by DealForma

Biotech and Pharma M&A in 2020

Biotech and Pharma M&A in 2020

Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. We look at the extensive DealForma database to see how life sciences M&A activity shaped up in 2020 in more detail.

read more

You met on Zoom. Now it's Deal Time.

With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.